Code Bio: Using DNA scaffolds to deliver non-viral gene therapies

Non-viral gene therapy start-up Code Bio believes its synthetic DNA vectors will allow it to deliver payloads that viral vectors cannot, opening up broader possibilities for the modality including repeat dosing, specific cell targeting, and a wider range of target indications. 

Spun out of Philadelphia-area tools and diagnostics company Genisphere LLC in April 2020, Code Biotherapeutics Inc. first intends to bring programs for Duchenne muscular dystrophy and Type I diabetes toward the clinic. Philanthropic foundations associated with each disease joined VCs in the start-up’s $10 million seed round, announced this week...